NCT07482137 (EA for DFU) is a NA clinical trial of Electroacupuncture at Zusanli (ST-36) in Diabetes Foot Care, sponsored by Zhongda Hospital.

Who is sponsoring NCT07482137?

NCT07482137 is sponsored by Zhongda Hospital.

What drugs are being tested in NCT07482137?

Interventions in NCT07482137: Electroacupuncture at Zusanli (ST-36).

What condition does NCT07482137 study?

NCT07482137 studies Diabetes Foot Care.

Is NCT07482137 still recruiting?

NCT07482137 is currently recruiting now. Last updated 19 March 2026.

Last reviewed 2026-03-19 · How we verify

NCT07482137: EA for DFU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Effect of Electroacupuncture at Zusanli (ST-36) on Diabetic Foot Wounds

Recruiting now NA Last updated 19 March 2026

What this trial tests

NA trial testing Electroacupuncture at Zusanli (ST-36) in Diabetes Foot Care in 76 participants. Currently enrolling.

Timeline

15 July 2025

Primary endpoint
30 September 2027

31 December 2027

Quick facts

Lead sponsor	Zhongda Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	76
Start date	15 July 2025
Primary completion	30 September 2027
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

Electroacupuncture at Zusanli (ST-36)

Conditions studied

Diabetes Foot Care — all drugs for Diabetes Foot Care →

Sponsor

Zhongda Hospital

Who can join

Adults 18 to 75, any sex, with Diabetes Foot Care. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if electroacupuncture at the Zusanli (ST-36) can assist in the treatment of diabetic foot ulcers. The main question it aims to answer is: Can electroacupuncture at the Zusanli (ST-36) promote wound healing in patients with diabetic foot ulcers? Researchers will compare outcomes between participants receiving electroacupuncture plus standard treatment and those receiving standard treatment alone to assess the effect of Zusanli (ST36) stimulation on wound healing in patients with diabetic foot ulcers. Participants will: Receive standard diabetes treatment (including diabetes education, dietary control, insulin combined with oral hypoglycemic agents to manage blood glucose, and effective antibiotics to control infection. For patients with foot ulcers, the wound will be cleaned with saline; abscesses will be drained if present; daily dressing changes.) Participants in the electroacupuncture group will receive electroacupuncture at Zusanli(ST-36) every day; 6 sessions constitute one treatment course, for a total of 4 courses. Visit the hospital for examinations before treatment and after each treatment course to measure the ankle-brachial index (ABI), assess diabetic foot Wagner grade, and evaluate hemodynamic parameters.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Foot Care

Currently open trials in the same condition.

NCT07462741 — The Effectiveness of Education in Diabetic Hemodialysis Patients · NA · recruiting

Other Zhongda Hospital trials

Trials by the same sponsor.

NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07482137 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
Last refreshed: 19 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07482137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing